GEN3017
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classical Hodgkin Lymphoma
Conditions
Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Trial Timeline
Sep 21, 2023 → Feb 5, 2025
NCT ID
NCT06018129About GEN3017
GEN3017 is a phase 1/2 stage product being developed by Genmab for Classical Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT06018129. Target conditions include Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06018129 | Phase 1/2 | Terminated |
Competing Products
11 competing products in Classical Hodgkin Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Camrelizumab + Investigator's choice of Chemotherapy | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Sabestomig (AZD7789) | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotin | Merck | Phase 2 | 52 |
| Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + Prednisone | Merck | Phase 2 | 52 |
| Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine Sulfate | Merck | Phase 2 | 52 |
| Carboplatin + Etoposide + Ifosfamide + Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab (+) Berahyaluronidase alfa | Merck | Phase 2 | 52 |
| Panobinostat | Novartis | Phase 2 | 52 |
| PD1 | Innovent Biologics | Phase 2 | 51 |
| Nivolumab + Autologous CD30.CAR-T + Fludarabine + Bendamustine | Bristol Myers Squibb | Phase 1 | 32 |
| Tislelizumab + Salvage Chemotherapy | BeOne Medicines | Phase 3 | 74 |